In today’s session Davita Inc (DVA) registered an unusually high (2,086) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious DVA increase. With 2,086 contracts traded and 314 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: DVA161118C00055000 closed last at: $2.4 or 4% down. About 657,851 shares traded hands. Davita Inc (NYSE:DVA) has declined 19.73% since March 30, 2016 and is downtrending. It has underperformed by 22.75% the S&P500.
Davita Inc (NYSE:DVA) Ratings Coverage
Out of 6 analysts covering DaVita (NYSE:DVA), 1 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 17% are positive. $83 is the highest target while $71 is the lowest. The $73.25 average target is 26.16% above today’s ($58.06) stock price. DaVita has been the topic of 11 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Wednesday, November 4, the company rating was maintained by RBC Capital Markets. JP Morgan maintained the stock with “Neutral” rating in Tuesday, August 9 report. RBC Capital Markets maintained the stock with “Sector Perform” rating in Thursday, August 6 report. On Tuesday, September 6 the stock rating was initiated by Citigroup with “Neutral”. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, February 16. Bernstein maintained the shares of DVA in a report on Wednesday, March 2 with “Market Perform” rating. JP Morgan initiated the stock with “Neutral” rating in Wednesday, September 16 report. Raymond James upgraded the stock to “Outperform” rating in Tuesday, September 20 report. The stock has “Neutral” rating given by Bank of America on Tuesday, September 6.
According to Zacks Investment Research, “DaVita Inc. is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a provider of kidney care, delivering dialysis services for chronic kidney failure and end stage renal disease primarily in the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks primarily in California, Nevada, New Mexico, Florida, Colorado and Washington. DaVita Inc., formerly known as DaVita HealthCare Partners Inc., is headquartered in Denver, Colorado.”
Insitutional Activity: The institutional sentiment increased to 1.04 in Q2 2016. Its up 0.03, from 1.01 in 2016Q1. The ratio is positive, as 34 funds sold all Davita Inc shares owned while 162 reduced positions. 51 funds bought stakes while 153 increased positions. They now own 171.18 million shares or 3.23% less from 176.89 million shares in 2016Q1.
Old Mutual Customised Solutions (Proprietary) Ltd has 2,200 shares for 0.04% of their US portfolio. Shinko Asset Management Limited holds 3,142 shares or 0% of its portfolio. Marshall Wace Llp owns 606,232 shares or 0.39% of their US portfolio. The Massachusetts-based Putnam Llc has invested 0.02% in Davita Inc (NYSE:DVA). Moreover, Fuller & Thaler Asset Mngmt has 0.09% invested in Davita Inc (NYSE:DVA) for 66,465 shares. Bridgewater Associates Ltd Partnership reported 75,970 shares or 0.07% of all its holdings. Jarislowsky Fraser reported 1.32M shares or 0.71% of all its holdings. Comerica Retail Bank has invested 0.05% of its portfolio in Davita Inc (NYSE:DVA). Glenmede Tru Comm Na accumulated 0% or 5,785 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt Systems has 0.02% invested in the company for 13,062 shares. Seabridge Advsr Lc has invested 0% of its portfolio in Davita Inc (NYSE:DVA). Profund Advisors has 6,733 shares for 0.03% of their US portfolio. Frontier Cap Co Limited Liability Co reported 258 shares or 0% of all its holdings. Bb&T Lc holds 0.02% of its portfolio in Davita Inc (NYSE:DVA) for 13,183 shares. Becker accumulated 181,440 shares or 0.57% of the stock.
Insider Transactions: Since May 6, 2016, the stock had 0 insider buys, and 12 sales for $12.53 million net activity. On Tuesday, May 10 the insider Kogod Dennis sold $3.05 million. Shares for $1.48M were sold by STAFFIERI MICHAEL DAVID. Another trade for 1,291 shares valued at $101,360 was sold by JIGANTI JEANINE MARIE. Another trade for 36,466 shares valued at $2.75 million was made by Rodriguez Javier on Friday, May 13. The insider ZUMWALT LEANNE M sold 538 shares worth $41,469. NEHRA JOHN M had sold 16,314 shares worth $1.23M. Valine Roger had sold 8,220 shares worth $627,534 on Thursday, May 12.
DaVita Inc., formerly DaVita HealthCare Partners Inc., is a well-known provider of kidney care services. The company has a market cap of $12.77 billion. The Firm operates Kidney Care division and HealthCare Partners division. It has a 34.3 P/E ratio. The Company’s divisions include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives.
DVA Company Profile
DaVita Inc., formerly DaVita HealthCare Partners Inc., incorporated on April 4, 1994, is a well-known provider of kidney care services. The Firm operates Kidney Care division and HealthCare Partners (HCP) division. The Company’s divisions include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. The Company’s Kidney Care division is a well-known provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). HCP division is a patient and physician-focused integrated health care delivery and management company.
More recent Davita Inc (NYSE:DVA) news were published by: Investorplace.com which released: “Why Brocade Communications Systems, Inc. (BRCD), Davita Inc (DVA) and …” on October 31, 2016. Also Prnewswire.com published the news titled: “DaVita is a Clinical Leader in Government Five-Star Rating System” on October 24, 2016. Prnewswire.com‘s news article titled: “DaVita Inc. Schedules 3rd Quarter 2016 Investor Conference Call” with publication date: October 07, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.